Royalty Pharma Plc
(NASDAQ : RPRX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.54%53.700.9%$1400.96m
JNJJohnson & Johnson 0.66%180.650.7%$1304.46m
BMYBristol-Myers Squibb Co. -2.28%75.831.0%$1184.67m
MRKMerck & Co., Inc. 0.36%92.640.7%$1171.07m
ABBVAbbVie, Inc. -0.75%149.441.9%$1092.12m
LLYEli Lilly & Co. 2.44%321.111.1%$990.82m
AZNAstraZeneca Plc 0.73%67.191.0%$495.11m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.06%143.270.0%$492.89m
NVSNovartis AG 0.15%91.400.2%$260.25m
VERUVeru, Inc. 0.71%12.730.0%$255.51m
GSKGlaxoSmithKline Plc -0.95%44.000.2%$255.16m
HZNPHorizon Therapeutics Plc 3.83%94.065.4%$203.54m
SGENSeagen Inc. 1.74%140.875.7%$188.90m
NVONovo Nordisk A/S 0.77%107.420.1%$184.27m
VTRSViatris, Inc. 1.54%12.200.0%$167.88m

Company Profile

Royalty Pharma Plc provides drug development services. The firm operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.